Pharmacological chaperone corrects lysosomal storage in Fabry disease caused by trafficking-incompetent variants.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  American Journal of Physiology - Cell Physiology

• Publication date

  2006-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1152/AJPCELL.00426.2005PMID 16531566
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A synthetic chaperone corrects the trafficking defect and disease phenotype in a protein misfolding disorder

  2005influential reference
• Pharmacologic Rescue of Conformationally‐Defective Proteins: Implications for the Treatment of Human Disease

  2004cited by this paper
• Correlation between enzyme activity and substrate storage in a cell culture model system for Gaucher disease

  2004cited by this paper
• A Cure for Traffic Jams: Small Molecule Chaperones in the Endoplasmic Reticulum

  2004cited by this paper
• Checkpoints in ER-associated degradation: excuse me, which way to the proteasome?

  2004cited by this paper
• The GGA proteins: key players in protein sorting at the trans-Golgi network.

  2004cited by this paper
• Enzyme replacement and enhancement therapies for lysosomal diseases

  2004cited by this paper
• AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.

  2004cited by this paper
• Chemical Chaperones — A New Concept in Drug Research

  2003cited by this paper
• Protein folding and misfolding

  2003cited by this paper
• Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.

  2003cited by this paper
• Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer

  2003cited by this paper
• Chemical chaperone therapy for brain pathology in GM1-gangliosidosis

  2003cited by this paper
• Gaucher and Fabry diseases: from understanding pathophysiology to rational therapies

  2003cited by this paper
• Quality control in the endoplasmic reticulum

  2003cited by this paper
• Quality control in the endoplasmic reticulum protein factory

  2003cited by this paper
• Chemical Chaperones—A New Concept in Drug Research

  2003cited by this paper
• Chemical chaperones increase the cellular activity of N370S β-glucosidase: A therapeutic strategy for Gaucher disease

  2002cited by this paper
• Traffic Jams II: An Update of Diseases of Intracellular Transport

  2002cited by this paper
• Adenovirus-transduced lung as a portal for delivering alpha-galactosidase A into systemic circulation for Fabry disease.

  2002cited by this paper
• Protein N-glycosylation along the secretory pathway: relationship to organelle topography and function, protein quality control, and cell interactions.

  2002cited by this paper
• α-Galactosidase A deficiency. Fabry disease

  2001cited by this paper
• The Metabolic and Molecular Bases of Inherited Disease

  2001cited by this paper
• Preselective gene therapy for Fabry disease

  2001cited by this paper
• Golgi apparatus immunolocalization of endomannosidase suggests post-endoplasmic reticulum glucose trimming: implications for quality control.

  2000cited by this paper
• In vitro inhibition and intracellular enhancement of lysosomal alpha-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives.

  2000cited by this paper
• Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.

  2000cited by this paper
• Role of Ser-65 in the activity of alpha-galactosidase A: characterization of a point mutation (S65T) detected in a patient with Fabry disease.

  2000cited by this paper
• Accelerated transport and maturation of lysosomal α–galactosidase A in Fabry lymphoblasts by an enzyme inhibitor

  1999influential reference
• Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.

  1997cited by this paper
• The trans-Golgi network: a late secretory sorting station.

  1997cited by this paper
• Aggregation of the Inactive Form of Human α-Galactosidase in the Endoplasmic Reticulum

  1996cited by this paper
• Aggregation of the inactive form of human alpha-galactosidase in the endoplasmic reticulum.

  1996cited by this paper
• A method for the isolation and serial propagation of keratinocytes, endothelial cells, and fibroblasts from a single punch biopsy of human skin

  1995cited by this paper
• N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing.

  1994cited by this paper
• Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease

  1992cited by this paper
• Quality control in the endoplasmic reticulum: folding and misfolding of vesicular stomatitis virus G protein in cells and in vitro

  1990cited by this paper
• The biogenesis of lysosomes.

  1989cited by this paper
• Postembedding labeling on Lowicryl K4M tissue sections: detection and modification of cellular components.

  1989cited by this paper
• Practical methods for biological morphometry

  1979cited by this paper
• A study of positive staining of ultrathin frozen sections.

  1978cited by this paper

• Endoplasmic reticulum stress as a driver and therapeutic target for kidney disease

  2025cites this paper
• New Drugs Available for Fabry Disease

  2025cites this paper
• Pathogenicity of novel GLA gene missense mutations in Fabry disease and the therapeutic impact of migalastat

  2025cites this paper
• Glycosphingolipids in Cardiovascular Disease: Insights from Molecular Mechanisms and Heart Failure Models

  2024cites this paper
• Fabry disease enzyme enhancement on migalastat study: FEES.

  2024cites this paper
• Terra incognita of glial cell dynamics in the etiology of leukodystrophies: Broadening disease and therapeutic perspectives.

  2024cites this paper
• Dominantly acting variants in ATP6V1C1 and ATP6V1B2 cause a multisystem phenotypic spectrum by altering lysosomal and/or autophagosome function

  2024cites this paper
• A Systematic Review on Safety and Efficacy of Migalastat for the treatment of Fabry’s Disease

  2024cites this paper
• Fabry Disease: Switch from Enzyme Replacement Therapy to Oral Chaperone Migalastat: What Do We Know Today?

  2023cites this paper
• Age-related neuroimmune signatures in dorsal root ganglia of a Fabry disease mouse model

  2023cites this paper
• Pharmacological Chaperones and Protein Conformational Diseases: Approaches of Computational Structural Biology

  2023cites this paper
• Quantifying lysosomal glycosidase activity within cells using bis-acetal substrates

  2022cites this paper
• Brazilian consensus recommendations for the diagnosis, screening, and treatment of individuals with fabry disease: Committee for Rare Diseases - Brazilian Society of Nephrology/2021

  2022cites this paper
• Activation of mitochondrial TRAP1 stimulates mitochondria-lysosome crosstalk and correction of lysosomal dysfunction

  2022cites this paper
• Chaperone Therapy in Fabry Disease

  2022cites this paper
• Sphingolipid lysosomal storage diseases: from bench to bedside

  2021influential citation
• Renal Manifestations of Fabry Disease: A Narrative Review

  2021cites this paper
• Stereoselective synthesis of novel carbocyclic and heterocyclic scaffolds of medicinal importance from biocatalytically derived enantiopure α-substituted-β-hydroxy esters

  2021cites this paper
• [Chaperone molecules: The example of Fabry disease].

  2021cites this paper
• Fabry disease: genetics, pathology, and treatment.

  2020cites this paper
• Fabry Disease Therapy: State-of-the-Art and Current Challenges

  2020cites this paper
• Misfolding of Lysosomal α-Galactosidase a in a Fly Model and Its Alleviation by the Pharmacological Chaperone Migalastat

  2020cites this paper
• Chaperoning Endoplasmic Reticulum-Associated Degradation (ERAD) and Protein Conformational Diseases.

  2019cites this paper
• Therapies for Lysosomal Storage Diseases

  2019cites this paper
• Inter-assay variability influences migalastat amenability assessments among Fabry disease variants.

  2019cites this paper
• Advances in the Development of Pharmacological Chaperones for the Mucopolysaccharidoses

  2019cites this paper
• C -Branched Imino Sugars: Synthesis and Biological Relevance

  2019cites this paper
• Pharmacological Chaperones for the Mucopolysaccharidoses

  2019cites this paper
• Therapeutic strategies for diseases caused by loss-of-function mutations in G protein-coupled receptors.

  2019cites this paper
• Migalastat: A Review in Fabry Disease

  2019cites this paper
• A Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometric Assay for the Quantification of Fabry Disease Biomarker Globotriaosylceramide (GB3) in Fabry Model Mouse

  2018cites this paper
• Application of sequential proline-catalyzed α-chlorination and aldol reactions in the total synthesis of 1-deoxygalactonojirimycin

  2018cites this paper
• Pharmacological chaperones for the misfolded melanocortin-4 receptor associated with human obesity.

  2017cites this paper
• In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease.

  2017cites this paper
• Recent advances and novel treatments for sphingolipidoses.

  2017cites this paper
• Fluorescent probes for selective protein labeling in lysosomes: a case of α‐galactosidase A

  2017cites this paper
• Small-Molecule Modulation of Protein Homeostasis.

  2017cites this paper
• Pharmacological characterization and functional rescue of the giant panda and human melanocortin-4 receptors

  2017cites this paper
• The validation of pharmacogenetics for the identification of Fabry patients to be treated with migalastat

  2016cites this paper
• Pharmacological Chaperones as Potential Therapeutics for Lysosomal Storage Disorders: Preclinical Research to Clinical Studies

  2016cites this paper
• Double-target Antisense U1snRNAs Correct Mis-splicing Due to c.639+861C>T and c.639+919G>A GLA Deep Intronic Mutations

  2016cites this paper
• Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features

  2016cites this paper
• Endoplasmic reticulum stress in chondrodysplasias caused by mutations in collagen types II and X

  2016cites this paper
• Pharmacoperones as a New Therapeutic Approach: In Vitro Identification and In vivo Validation of Bioactive Molecules.

  2016cites this paper
• Personalized Pharmacoperones for Lysosomal Storage Disorder: Approach for Next-Generation Treatment.

  2016cites this paper
• Carbohydrate-Processing Enzymes of the Lysosome: Diseases Caused by Misfolded Mutants and Sugar Mimetics as Correcting Pharmacological Chaperones.

  2016cites this paper
• Pharmacological Chaperone Therapy: Preclinical Development, Clinical Translation, and Prospects for the Treatment of Lysosomal Storage Disorders.

  2015cites this paper
• Coformulation of a Novel Human α-Galactosidase A With the Pharmacological Chaperone AT1001 Leads to Improved Substrate Reduction in Fabry Mice

  2015cites this paper
• Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase

  2015cites this paper
• Cell biology of protein glycosylation: a celebration of the career of Jürgen Roth on the occasion of his 70th birthday

  2014cites this paper
• Pharmacological chaperoning: a primer on mechanism and pharmacology.

  2014cites this paper
• Pharmacological characterization and functional rescue of human melanocortin-4 receptor mutants

  2014cites this paper
• Fabry's disease.

  2014cites this paper
• An asymmetric substrate-controlled Morita–Baylis–Hillman reaction as approach for the synthesis of pyrrolizidinones and pyrrolizidines

  2014cites this paper
• Altered dynamics of a lipid raft associated protein in a kidney model of Fabry disease.

  2014cites this paper
• A thermodynamic assay to test pharmacological chaperones for Fabry disease

  2014cites this paper
• Estudio funcional de variantes en el gen GLA: implicación en la heterogeneidad clínica de la enfermedad de Fabry y en su tratamiento

  2013cites this paper
• Unfolded protein response in Gaucher disease: from human to Drosophila

  2013cites this paper
• Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients

  2013cites this paper
• Pulmonary involvement in Anderson Fabry Disease

  2013cites this paper
• The effectiveness and cost of enzyme replacement and substrate reduction therapies : a longitudinal cohort study of people with lysosomal storage disorders

  2013cites this paper
• Pharmacokinetics, safety, and tolerability following single-dose migalastat hydrochloride (GR181413A/AT1001) in healthy male Japanese subjects

  2013cites this paper
• Review Pharmacological chaperone therapy for Fabry disease

  2012cites this paper
• Single Gene Disorders Associated With Stroke: A Review and Update on Treatment Options

  2012cites this paper
• Isolation and Identification of Myo-Inositol Crystals from Dragon Fruit (Hylocereus polyrhizus)

  2012cites this paper
• Neurological features of Fabry disease: clinical, pathophysiological aspects and therapy

  2012cites this paper
• Co-administration With the Pharmacological Chaperone AT1001 Increases Recombinant Human α-Galactosidase A Tissue Uptake and Improves Substrate Reduction in Fabry Mice

  2012cites this paper
• The delicate balance between secreted protein folding and endoplasmic reticulum-associated degradation in human physiology.

  2012cites this paper
• α-Galactosidase Aggregation Is a Determinant of Pharmacological Chaperone Efficacy on Fabry Disease Mutants*

  2012cites this paper
• Fabry disease: raising awareness of the disease among physicians

  2012cites this paper
• Convenient synthesis of 4-thiolactose, 3,4-dithiolactose and related thiooligosaccharides and disulfides. Inhibitory activity of the glycomimetics against a β-galactosidase.

  2012cites this paper
• Systematic Structure–Activity Study on Potential Chaperone Lead Compounds for Acid α‐Glucosidase

  2012cites this paper
• Pharmacological chaperone therapy for Fabry disease

  2012cites this paper
• A Pharmacogenetic Approach to Identify Mutant Forms of α-Galactosidase A that Respond to a Pharmacological Chaperone for Fabry Disease

  2011influential citation
• The molecular basis of pharmacological chaperoning in human α-galactosidase.

  2011cites this paper
• Molecular mechanism for stabilization of a mutant α-galactosidase A involving M51I amino acid substitution by imino sugars.

  2011cites this paper
• Corneal Manifestations of Metabolic Diseases

  2011cites this paper
• Identification and characterization of pharmacological chaperones to correct enzyme deficiencies in lysosomal storage disorders.

  2011influential citation
• Treatment of fabry disease: current and emerging strategies.

  2011cites this paper
• Therapy of Fabry disease with pharmacological chaperones: from in silico predictions to in vitro tests

  2011cites this paper
• Protein N-glycosylation, protein folding, and protein quality control

  2010cites this paper
• Function and regulation of phenylalanine and tyrosine hydroxylases from human and Caenorhabditis elegans. With focus in evolutionary aspects and development of new therapies

  2010cites this paper
• Prediction of the clinical phenotype of Fabry disease based on protein sequential and structural information

  2010cites this paper
• Inherited metabolic disorders and stroke part 1: Fabry disease and mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes.

  2010cites this paper
• Fabry Disease – Current Treatment and New Drug Development

  2010cites this paper
• The pharmacological chaperone 1-deoxygalactonojirimycin reduces tissue globotriaosylceramide levels in a mouse model of Fabry disease.

  2010cites this paper
• Functional studies of new GLA gene mutations leading to conformational Fabry disease.

  2010cites this paper
• Asymmetric synthesis of hydroxy-skipped bishomo-inositols as potential glycosidase inhibitors

  2010cites this paper
• Small Molecule Drug Discovery for Fabry Disease

  2010cites this paper
• Sodium 4-phenylbutyrate ameliorates the effects of cataract-causing mutant gammaD-crystallin in cultured cells

  2010cites this paper
• Fabry disease

  2010cites this paper
• Sugar-mimicking glycosidase inhibitors: bioactivity and application

  2009cites this paper
• Effects of pH and iminosugar pharmacological chaperones on lysosomal glycosidase structure and stability.

  2009cites this paper
• Correction of the disease phenotype of myocilin-causing glaucoma by a natural osmolyte.

  2009cites this paper
• Lysosomal Storage Disorders in the Newborn

  2009cites this paper
• The pharmacological chaperone 1-deoxygalactonojirimycin increases α-galactosidase A levels in Fabry patient cell lines

  2009influential citation
• Glycosidase inhibition: assessing mimicry of the transition state

  2009cites this paper
• Molecular interaction of imino sugars with human alpha-galactosidase: Insight into the mechanism of complex formation and pharmacological chaperone action in Fabry disease.

  2009cites this paper
• [Fabry disease].

  2009cites this paper
• Effects of a chemical chaperone on genetic mutations in α-galactosidase A in Korean patients with Fabry disease

  2009cites this paper